ACTIVE_NOT_RECRUITING

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Hot flashes and night sweats (also known as vasomotor symptoms or VMS) are the most common symptoms which bother women in menopause. This study will follow women going through menopause who have hot flashes and night sweats that cause them bother. They will be starting a non-hormonal therapy prescribed by their healthcare provider (HCP) to treat these symptoms. The women will visit their HCP's office, research center, or both. They will receive prescriptions for the non-hormonal therapy from their HCP for up to 1 year. This real-world study will provide information on outcomes from various non-hormonal therapies. The study sponsor (Astellas) will not decide which therapy the women receive. However, the sponsor will provide instructions on when the women visit their clinic, and what is recorded during the study. Some of the visits will be in-person, but most will be virtual. The virtual visits can be carried out at home using a smartphone, tablet or computer. The main aim of the study is to check if the hot flashes and night sweats that bother women change after 12 weeks (3 months) of treatment. The study will also check the women's sleep patterns, their productivity at work, and their general well-being before and after starting treatment. The overall safety of the non-hormonal therapies will also be examined.

Official Title

A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms

Quick Facts

Study Start:2023-11-15
Study Completion:2026-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06049797

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 75 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participant is diagnosed with bothersome VMS due to/associated with menopause for at least 3 months based on a standard of care assessment captured in consultation with an HCP including the participant's history, routine physical examination, and routine laboratory assessments.
  2. * HCP has made the clinical decision to begin pharmacologic treatment with a non-HT including, a selective neurokinin 3 receptor (NK3-R) antagonist, an SSRI, SNRI, gabapentin, clonidine, pregabalin, oxybutynin or other non-HT, as part of the standard treatment for VMS. This may be the first course of treatment, a restart or a switch from one drug (HT/non- HT) to another non-HT. A restart or switch of a previous therapy requires a minimum of a 10-day period not on therapy/washout period prior to pre-baseline.
  3. * Participant's health status is stable based on their medical history and general physical exam and determined to be a candidate for treatment with non-HTs.
  4. * If participant has been prescribed an SSRI or SNRI for the treatment of depression or anxiety, they must be on a stable or consistent dose for a minimum of 3 months prior to screening.
  5. * Participant has a negative urine pregnancy test at screening if not post-menopausal.
  6. * Only for participants utilizing complementary and alternative therapies, mind-body techniques, or supplements for the treatment of VMS: participant has been on such therapies for ≥ 3 months prior to screening and intends to continue through duration of study.
  7. * Confirmation has been made that the participant is able to obtain the prescribed non hormonal therapy (e.g., insurance coverage verified, participant has ability to self pay, or patient support program activated for at least 12 months for the uninsured participants, if applicable).
  1. * Participant is currently enrolled in any interventional or non-interventional wearable device study.
  2. * Participant has any condition which makes the participant unsuitable for the study.
  3. * Participant has a contraindication to the non-HT they are being prescribed for the treatment of VMS.
  4. * Participant is currently taking hormonal contraceptives or other systemic HTs (including estrogen and/or progesterone, and/or testosterone preparations) and has not had a 10-day washout period prior to pre-baseline (vaginal/local estrogen preparations and levonorgestrel-releasing intrauterine system are not prohibited).
  5. * Participant has presence of moderately severe or severe depression per standard of care assessment utilizing a standardized depression screening tool.
  6. * Participant is currently pregnant or planning to become pregnant.
  7. * Participant is post-menopausal and has a history of unexplained uterine bleeding within the last 6 months.
  8. * Participant has pre-existing uncontrolled thyroid disease.
  9. * Participant has unstable angina or participant has uncontrolled hypertension based on a standard of care assessment.
  10. * Participants who do not meet these criteria may be re-assessed after initiation or review of antihypertensive measures.
  11. * Participants with a medical history of hypertension can be enrolled once they are medically clear (stable and compliant).
  12. * Participant has had insomnia unrelated to either menopause or bothersome VMS due to/associated with menopause.
  13. * Participant has known substance abuse or alcohol addiction within 6 months of screening.
  14. * Participant has been on intramuscular estradiol within 8 weeks of screening.
  15. * Participant has a current diagnosis of a malignancy or history of a malignancy within the past 2 years (This does not include basal cell carcinoma or breast cancer.)
  16. * Participants with metastatic (Stage 4) breast cancer.
  17. * Participants who have been prescribed adjuvant endocrine therapy (tamoxifen or aromatase inhibitors with or without gonadotropin-releasing hormone analogues) for their non-metastatic (stage 0 to 3) breast cancer but have not maintained a stable treatment regimen for at least 3 months prior to screening.
  18. * Participant has initiated hormone pellet therapy within 6 months of screening.

Contacts and Locations

Principal Investigator

Central Contact
STUDY_DIRECTOR
Astellas Pharma Global Development, Inc.

Study Locations (Sites)

Alabama Clinical Therapeutics
Birmingham, Alabama, 35205
United States
Accel Research Sites-Cahaba Medical Care-OBGYN
Birmingham, Alabama, 35218
United States
Precision Trials AZ, LLC
Phoenix, Arizona, 85032
United States
Torrance Clinical Research Institute,Inc
Lomita, California, 90717
United States
Dream Team Clinical Research
Pomona, California, 91767
United States
Wake Research - Medical Center for Clinical Research WR-MCCR, LLC
San Diego, California, 92120
United States
Millennium Clinical Trials LLC
Simi Valley, California, 93065
United States
Bayview Research Group, LLC
Valley Village, California, 91607
United States
University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus
Aurora, Colorado, 80045
United States
Accel Research Sites
DeLand, Florida, 32720
United States
Nextlevel Research Center
Doral, Florida, 33172
United States
Multi-Specialty Research Associates, Inc. (WR-MSRA, LLC)
Lake City, Florida, 32055
United States
Altus Research
Lake Worth, Florida, 33461
United States
Suncoast Research Associates, LLC
Miami, Florida, 33173
United States
Dr. Jarrett's Wellness Center
Miami, Florida, 33186
United States
Complete Health Research
Ormond Beach, Florida, 32174
United States
Comprehensive Clinical Trials, Llc
West Palm Beach, Florida, 33409
United States
Agile Clinical Research Trials, LLC
Atlanta, Georgia, 30342
United States
Alpha Clinical Research Georgia
Dunwoody, Georgia, 30350
United States
Clinical Research Prime
Idaho Falls, Idaho, 83404
United States
Rosemark Women Care Specialists
Idaho Falls, Idaho, 83404
United States
Chicago Clinical Research Institute Inc.
Chicago, Illinois, 60607
United States
Investigators Research Group, Llc
Brownsburg, Indiana, 46112
United States
Tekton Research
Wichita, Kansas, 67218
United States
Praetorian Pharmaceutical Research
Marrero, Louisiana, 70072
United States
Southern Clinical Research Associates
Metairie, Louisiana, 70001
United States
Saginaw Valley Medical Research Group, LLC
Saginaw, Michigan, 48604
United States
Montana Medical Research, Inc.
Missoula, Montana, 59808
United States
Bosque Women's Care
Albuquerque, New Mexico, 87109
United States
Upstate Clinical Research Associates
Williamsville, New York, 14221
United States
Premier Gynecology & Wellness
Charlotte, North Carolina, 28207
United States
Eastern Carolina Women's Center
New Bern, North Carolina, 28562
United States
Unified Women's Clinical Research
Winston-Salem, North Carolina, 27103
United States
HWC Women's Research Center
Englewood, Ohio, 45322
United States
Tekton Research
Moore, Oklahoma, 73160
United States
Clinical Research Of Philadelphia, Llc
Philadelphia, Pennsylvania, 19114
United States
Reading Hospital / Tower Health
West Reading, Pennsylvania, 19611
United States
Biocentric Health Research
West Columbia, South Carolina, 29169
United States
Chattanooga Medical Research, Llc
Chattanooga, Tennessee, 37404
United States
Signature Gyn Services
Fort Worth, Texas, 76104
United States
UT Health Women's Research Center at Memorial City
Houston, Texas, 77024
United States
TMC Life Research, Inc
Houston, Texas, 77054
United States
Biopharma Informatic Research Center
Houston, Texas, 77084
United States
Pioneer Research Solutions, Inc
Houston, Texas, 77099
United States
ClinRx Research LLC
Plano, Texas, 75024
United States
DCT - Stone Oak, LLC dba Discovery Clinical Trials
San Antonio, Texas, 78258
United States
Granger Medical Clinic
Riverton, Utah, 84065
United States
Tidewater Physicians for Women
Norfolk, Virginia, 23502
United States
Tidewater Clinical Research Inc
Virginia Beach, Virginia, 23456
United States
Seattle Clinical Research Center
Seattle, Washington, 98104
United States

Collaborators and Investigators

Sponsor: Astellas Pharma Global Development, Inc.

  • Central Contact, STUDY_DIRECTOR, Astellas Pharma Global Development, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-15
Study Completion Date2026-11-30

Study Record Updates

Study Start Date2023-11-15
Study Completion Date2026-11-30

Terms related to this study

Keywords Provided by Researchers

  • fezolinetant
  • vasomotor symptoms
  • menopause
  • night sweats
  • non-hormonal treatment

Additional Relevant MeSH Terms

  • Hot Flashes